This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Sleep apnea prevalence in cardiology patients was similar to the rates in patients with heartfailure., and sleep apnea prevalence in cardio-oncology patients was the same or greater than other traditional riskfactors.
The findings – published this week in the Journal of the American College of Cardiology — could fuel advocacy for a paradigm shift in clinical heart health guidelines to address cardiovascular riskfactors at an earlier age in childhood cancer survivors. “We
Objectives This study aimed to identify the incidence of early cancer therapy-related cardiac dysfunction (CTRCD) and the behaviours of left and right heart deformations during trastuzumab chemotherapy in low- and moderate-risk patients. Results Twelve (10.9%) patients had asymptomatic CTRCD.
Patients with recurrent or advanced-stage breast cancer, with a history of heartfailure, receiving neoadjuvant chemotherapy or a preoperative history of less than 6 months were excluded. Results We identified 12 060 eligible patients (mean age 50.8±8.56 years) between January 2010 and December 2019. preoperative, 66.0%
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Cardio Oncology 
59 
Let's personalize your content